Posted by Michael Wonder on 20 Feb 2024
PepGen receives US FDA fast track designation for PGN-EDODM1 for the treatment of myotonic dystrophy type 1
20 February 2024 - PepGen today announced that the US FDA has granted fast track designation to PGN-EDODM1, an investigational candidate for the treatment of myotonic dystrophy type 1.
The Company previously announced that the FDA granted orphan drug designation to PGN-EDODM1 in September 2023.
